Troikaa Pharmaceuticals

Troikaa Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat in India.
History.
Troikaa Pharmaceuticals limited was established in 1983 in Ahmedabad, Gujarat by Rajni V. Patel, one of the few pharmacy graduates of the first batch of L. M. College of Pharmacy, Ahmedabad in 1950. Ketan R. Patel is the current Chairman & Managing Director of the company. Milan R. Patel is Joint Managing Director of the company.
Litigation.
In 2016, Troikaa Pharmaceuticals filed a petition in Delhi High Court seeking license cancellation of Diclofenac Sodium Injection 75 mg/ml, manufactured by Themis Medicare Pvt Ltd and marketed by Novartis India Ltd. under the brand name Voveran 1ml. Troikaa claimed that the diclofenac sodium 75 mg/ml injection contained Transcutol-P which caused damage to the kidneys. 
In July 2018, India's Drug Regulator canceled the license granted to M/S Themis Medicare for the sale of Diclofenac injection 75 mg/ml containing Transcutol-P.
In 2012, Troikaa Pharmaceuticals filed a patent infringement suit in Ahmedabad district court against Ahmedabad-based Lincoln Pharmaceuticals and Delhi-based Akums Drug & Pharmaceuticals Ltd, saying the two companies had infringed upon its patented high concentration, low viscosity diclofenac injection. The case was continued by Gujarat High Court, and ordered to Akums Drugs not to infringe, and dismissed Lincoln Pharma's appeal.
In 2008, Troikaa filed a suit for infringement of design against a company manufacturing D-shaped tablets. The company had challenged that Troikaa's D shaped tablet registration was invalid. The suit was transferred to the High Court of Gujarat and later in its first case under the Designs Act, the High Court decided in favor of the Troikaa.